Sunday, 8 September 2019

07:15 - 08:15


BRM-03 | Daiichi Sankyo: Assessing HER2: expert insights and guidance

Room Thalie
Chair: Giuseppe Viale, Italy

001 7:15 - 7:18
Welcome and introduction
Giuseppe Viale, Italy

002 7:18 - 7:38
Addressing the challenges of HER2 testing in breast cancer
Giuseppe Viale, Italy

003 7:38 - 7:53
Testing HER2 in other solid tumours: looking at current practices

004 7:53 - 8:08
HER2- directed therapies in breast cancer: current recommendations and future expectations

005 8:08 - 8:15
Q&A and panel discussion
Giuseppe Viale, Italy


13:00 - 14:30


LS-01 | BMS: Biomarkers in immuno-oncology: perspectives from the pathologist & oncologist

Room Apollon Auditorium
Chair: Frederique Penault-Llorca, France

001 13:00 - 13:30
The I-O evolution: drawing from the past to shape the future
Frederique Penault-Llorca, France

002 13:30 - 14:00
Choosing the right treatment at the right time: insights into the patient journey
Josep M. Piulats, Spain

003 14:00 - 14:30
Technical considerations for biomarker testing: what’s now, what’s next?
Chris Abbosh, United Kingdom

LS-02 | MSD & AstraZeneca: BRCA testing to guide precision medicine: strengthening the foundations and building for the future 

Room Uranie/Calliope
Chair: Reinhard Büttner, Germany

001 13:00 - 13:05
Welcome and introduction
Reinhard Büttner, Germany

002 13:05 - 13:25
Optimising patient selection in ovarian cancer: the rationale for tumour BRCA testing
Reinhard Büttner, Germany

003
 13:25 - 13:45
The keys to quality in tumour BRCA testing
Marjolijn Ligtenberg, The Netherlands

004 13:45 - 14:05
BRCA testing in precision medicine beyond ovarian cancer
Michael Pishvaian, USA

005
 14:05 - 14:30
Q&A/Closing remarks
Reinhard Büttner, Germany

LS-03 | AstraZeneca: Are you prepared for routine tumour mutation burden (TMB) analysis in NSCLC?

Room Hermès 
Chair: Paul Hofman, France

001 13:00 – 13:05
Welcome & introduction
Paul Hofman, France

002 13:05 – 13:25
Predicting response to immunotherapy by measuring TMB using tissue or liquid biopsies
Lea Payen, France

003
13:25 – 13:50
Dissecting the key parameters underpinning exceptional execution of TMB analysis
Eun-Ang Raiber, United Kingdom

004
13:50 – 14:15
TMB standardisation and harmonisation: recommendations for consistent TMB assessment across assays and centres
Albrecht Stenzinger, Germany

005
14:15 – 14:30
Q & A
Paul Hofman, France

LS-04 | 3DHistech: Transition to an effective and complete digital pathology workflow

Room Clio
Chair: Marianne Tinguely, Switzerland

001 
Now, where is the AI that was promised to support us? 
Felix Faber, Switzerland

002
 
Implementation of virtual routine diagnostics for dermatopathology and fish
Marianne Tinguely, Switzerland

003
 
Scanner for routine diagnostics: selection process in practice
Witold Rezner, Switzerland

004
 
Context-intelligent deep learning for pathology and translational research
Johan Lundin, Switzerland

005
 
Platform for development of deep learning-based algorithms
Sami Blom, Switzerland

LS-05 | Roche: Advances in breast cancer care: exciting prospects in triple negative breast cancer and personalised cancer immunotherapy

Room Athéna 
Chairs: Tibor Tot, Sweden, Anna Sapino, Italy

001 13:00 – 13:10
Welcome & introduction
Anna Sapino, Italy
Tibor Tot, Sweden


002
13:10 – 13:30
Recent advances in breast cancer management: how clinician will need more diagnosis
Filippo Montemurro, Italy

003
13:30 – 13:50
Importance & challenges of triple negative breast cancer diagnosis
Sahin Aysegul, USA

004
13:50 – 14:10
PD-L1 as companion diagnosis in metastatic triple negative breast cancer
Magali Lacroix Triki, France

005
14:10 – 14:30
Discussion and Q&A
Tibor Tot, Sweden


Monday, 9 September 2019

07:15 - 08:15

BRM-01 | Bayer: Genomic profiling for driver mutations in cancer: NTRK gene fusions

Room Hermès 
Chair: Reinhard Büttner, Germany

001 07:15 – 07:20
Welcome & introduction
Reinhard Büttner, Germany

002
 07:20 – 07:30
Novel genetic markers: NTRK gene fusions
Giuseppe Viale, Italy

003
 07:30 – 07:45
Developments in driver mutation detection: focus on NTRK gene fusions
Reinhard Büttner, Germany

004
 07:45 – 08:05
Interactive case session
Reinhard Büttner, Germany
Giuseppe Viale, Italy


005
 08:05 – 08:15
Q&A
Reinhard Büttner, Germany
Giuseppe Viale, Italy


13:00 - 14:30

LS-06 | Thermo Fisher Scientific: True precision oncology with next generation sequencing. Can one test fit all needs? 

Room Clio
Chair: Albrecht Stenzinger, Germany

001
13:05 - 13:25
In true precision oncology, one size cannot fill all needs
Andy Felton, USA

002
13:25 - 13:45
Next generation sequencing in every pathology laboratory, are we ready?
José Costa, Portugal

003
13:45 - 14:05
Reliable identification of gene fusions by targeted RNA sequencing
Volker Endris, Germany

004 14:05 - 14:25
Biomarkers for immuno-oncology: tumour mutational load and beyond. The impact of a multidimensional approach
Phil Jermann, Switzerland

005 14:25 - 14:30
Closing
Albrecht Stenzinger, Germany

LS-07 | Novartis: Shifting biomarker paradigms in advanced/metastatic breast cancer – looking towards PIK3CA and beyond 

Room Thalie
Chair: Federico Rojo, Spain

001
13:00 - 13:05
Welcome and introduction
Federico Rojo, Spain

002
13:05 - 13:25
Emerging biomarkers in advanced/metastatic breast cancer from a clinician’s perspective
Fabrice André, France

003
13:25 - 13:30
Q&A
Fabrice André, France

004 13:30 - 13:45
Optimising laboratory workflows to include PIK3CA mutation testing in breast-cancer diagnostics
Federico Rojo, Spain

005 13:45 - 13:50
Q&A
Federico Rojo, Spain

006 13:50 - 14:05
Quality assurance issues for PIK3CA testing in practice
Michael Hummel, Germany

007 14:05 - 14:10
Q&A
Michael Hummel, Germany

008 14:10 - 14:25
Consensus or conflict: expert views on biomarker testing in advanced/metastatic breast cancer
All faculty

009
14:25 - 14:30
Meeting closure
Federico Rojo, Spain

LS-08 | MSD: NSCLC and beyond: practical considerations for PD-L1 implementation

Room Uranie/Calliope
Chair: Jaafar Bennouna, France

001
13:00 - 13:05
Welcome and introduction
Jaafar Bennouna, France

002
13:05 - 13:25
Relevance of PD-L1 testing in an evolving immuno-oncology landscape: overview and updates
Jaafar Bennouna, France

003
13:25 - 13:45
PD-L1 immune-based scoring approaches in non-lung cancer
Hans-Ulrich Schildhaus, Germany

004 13:45 - 14:10
Quality PD-L1 testing: an EQA perspective
Mogens Vyberg, Denmark

005 14:10 - 14:30
Q&A/Closing remarks
Jaafar Bennouna, France

LS-09 | AstraZeneca: From respectable to exceptional: advancing beyond existing PD-L1 test capabilities for histologic and cytologic NSCLC specimens

Room Hermès 
Chair: Paul Hofman, France

001
13:00 - 13:05
Welcome and introduction
Paul Hofman, France

002
13:05 - 13:30
Solving PD-L1 test dilemmas once and for all
Marius Ilie, France

003
13:30 - 13:55
Utility of cytologic specimens and preanalytical procedures for PD-L1 testing in NSCLC cytopathology
Birgit Guldhammer Skov, Denmark

004 13:55 - 14:15
Strategies for addressing the intrinsic source of error associated with PD-L1 scoring and interpretation
Bharat Jasani, Germany

005 14:15 - 14:25
Q&A
Paul Hofman, France

006 14:25 - 14:30
Closing remarks
Paul Hofman, France

LS-10 | Roche: Transforming patient care through diagnostic innovation: liquid biopsies & clinical decision support

Room Athéna 
Chair: Marc Denis, France

001
13:00 - 13:05
Welcome and introduction
Marc Denis, France

002
13:05 - 13:30
Clinical utility of liquid biopsy across technologies
Marc Denis, France

003
13:30 - 13:55
Using ctDNA NGS as early response marker for immunotherapy in NSCLC
Harry Groen, The Netherlands

004 13:55 - 14:20
Making sense of NGS complexity: clinical decision support tools
Markus Falk, Germany

005 14:20 - 14:30
Summary & future perspectives
Marc Denis, France


Tuesday, 10 September 2019

13:00 - 14:30

LS-11 | Agilent: PD-L1: Debate of experts

Room Gallieni 5
Chair: Nick Kirk, United Kingdom

Experts:

001 Matt Evans, United Kingdom
002 Thorsten Fureder, Austria
003 Soeren Nielsen, Denmark
004 Mark Schmid, Switzerland
005 Darlene Krohn, USA

LS-12 | AstraZeneca: High expectations, limited samples: ensuring tissue is no longer an issue for patients with lung cancer

Room Hermès 
Chair: Ales Ryska, Czech Republic

001
13:00 - 13:05
Welcome
Ales Ryska, Czech Republic

002
13:05 - 13:30
Best practice guidance for ensuring samples consistently meet the diagnostic obligations for targeted therapy 
Luca Brcic, Croatia

003
13:30 - 13:55
Panel testing or single gene testing: is there an optimal approach?
Reinhard Büttner, Germany

004 13:55 - 14:05
Q&A
Ales Ryska, Czech Republic

005 14:05 - 14:25
Multidisciplinary team management in practice: how can effective collaboration deliver high quality and timely patient care?
Ales Ryska, Czech Republic

006 14:25 - 14:30
Closing remarks
Ales Ryska, Czech Republic

LS-13 | Kyowa Kirin: Navigating the complexities of CTCL

Room Thalie
Chair: Rein Willemze, The Netherlands

001
 13:00 - 13:05
Welcome and introduction
Rein Willemze, The Netherlands

002
 13:05 - 13:25
Update on the dermatopathology of CTCL: classifying subtypes
Rein Willemze, The Netherlands

003
 13:25 - 13:50
Exploring all compartments: molecular and histopathological insights
Maxime Battistella, France

004 13:50 - 14:15
Diagnosing CTCL subtypes: challenges and unmet needs 
Ilske Oschlies, Germany

005 14:15 - 14:30
Panel discussion and summary
Rein Willemze, The Netherlands

LS-14 | Illumina: Changing paradigms: the utility and efficiency of Comprehensive Tumour Profiling in the pathology lab

Room Apollon Auditorium
Chair: Nicola Normanno, Italy

001
 
Transforming oncology with comprehensive genomic profiling
David Eberhard, USA

002 
Real world experience with – TruSight™ Oncology 500 a pan-cancer sequencing essay
Andrew Beggs, United Kingdom

003
 
SMP2: bringing the value of Comprehensive Genomic Profiling into a national health system
Rowena Sharpe, United Kingdom

004 
Q&A
Nicola Normanno, Italy

LS-15 | Biocartis - Genomic Health: Optimised treatment decisions for personalised medicine

Room Gallieni 4
Chair: Rick Baehner, USA

001
13:00 - 13:05
Introduction
Caroline Jans, Belgium

002
13:05 - 13:35
Idylla™ MSI testing in colorectal and endometrial cancer
Francisco Javier Matias-Guiu Guia, Spain

003
13:35 - 14:05
The importance of fast EGFR testing
Emmanuel Khalifa, France

004 14:05 - 14:30
Prediction with precision – guiding chemotherapy treatment in early breast cancer
Ulrike Nitz, Germany